The Latest on Medication Abortion Access: The Court Awaits the FDA Review Published: April 9, 2026

https://www.kff.org/quick-take/the-latest-on-medication-abortion-access-the-court-awaits-the-fda-review/?utm_campaign=KFF-This-Week&utm_medium=email&_hsenc=p2ANqtz-_0fyjaRxBxJSSdHYWyeztEPLNdkWaXc1sooFlaY_ZKt1RGZrbYTVDrh6vKQl1I6pxiMFnV6LcRljYeWccRnm8BVbfVDQ&_hsmi=413211268&utm_content=413211268&utm_source=hs_email “Despite calls from Republican leaders and anti-abortion organizations for the FDA to act quickly, the Louisiana district court has given the FDA until October 7, 2026, one month before the midterms, to file a report with the status of its review and any updated timeframe for completion. In the meantime, clinicians may continue to mail mifepristone to pregnant patients seeking abortions regardless of where they live